Phase I/II Study of Concurrent Abemaciclib and Adjuvant Radiotherapy in Patients with HR+, HER2−, High-Risk Breast Cancer
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S150
DOI: 10.1016/j.ijrobp.2026.06.233 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von Y. Song und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Song, Y., Zhai, Y., Lan, B., Zhao, X., Li, Z., Qiu, Z., Shen, X., Zhang, C., Sun, G., Chen, S., Fang, H., Jing, H., Wang, Y., Ma, F., & Wang, S. (2026). Phase I/II Study of Concurrent Abemaciclib and Adjuvant Radiotherapy in Patients with HR+, HER2−, High-Risk Breast Cancer. International Journal of Radiation Oncology*Biology*Physics, 126(1), S150. https://doi.org/10.1016/j.ijrobp.2026.06.233
Vancouver
Song Y, Zhai Y, Lan B, Zhao X, Li Z, Qiu Z, et al. Phase I/II Study of Concurrent Abemaciclib and Adjuvant Radiotherapy in Patients with HR+, HER2−, High-Risk Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S150. doi:10.1016/j.ijrobp.2026.06.233
BibTeX
@article{Song2026,
author = {Song, Y. and Zhai, Y. and Lan, B. and Zhao, X. and Li, Z. and Qiu, Z. and Shen, X. and Zhang, C. and Sun, G. and Chen, S. and Fang, H. and Jing, H. and Wang, Y. and Ma, F. and Wang, S.},
title = {Phase I/II Study of Concurrent Abemaciclib and Adjuvant Radiotherapy in Patients with HR+, HER2−, High-Risk Breast Cancer},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {S150},
doi = {10.1016/j.ijrobp.2026.06.233}
}
EUVIMED